Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment and Improvements

Equipment and Improvements

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]


Equipment and Improvements, net
	September 30,		December 31,
	2023		2022
Furniture and office equipment	$	86,930	$	72,692
Lab equipment		—		153,668
IT equipment		16,895		16,895
		103,825		243,255
Less: accumulated depreciation		23,885		6,723
Total	$	79,940	$	236,532

Depreciation expense for three and nine months ended September 30, 2023 was $6,568 and $170,830, respectively, and $1,681 for the three and nine months ended September 30, 2022.